期刊文献+

癌胚抗原低亲和力表位改造中的分子对接 被引量:2

Molecular docking simulations of low-affinity CTL epitopes and its analogue derived from carci- noembryonic antigen
下载PDF
导出
摘要 目的通过分子对接方法筛选表位改造后的高亲和力CTL表位。方法在图形工作站上,将癌胚抗原来源的低亲和力表位及其N末端第一位残基以酪氨酸替换后的突变体,分别与MHCⅠ类分子进行对接,对接所得最佳构象进行600ps分子动力学模拟修正。结果改造后的突变体与MHC分子间存在较强的氢键和疏水相互作用,组成肽结合槽口袋A的残基Tyr7、Tyr171和Tyr159与多肽N末端形成稳定的氢键作用网络,并且P1位酪氨酸上的苯环可与Trp167上的苯环发生ππ堆积作用。结论分子对接模型预测的肽MHC复合物作用模式,提示改造后的突变体与MHCⅠ类分子间具有更高的亲和力,与实验结果一致。 Objective To screen high-affinity peptide analogs of CTL epitopes by molecular docking. Methods Low-affinity CTL epitope derived from carcinoembryonic antigen (CEA) and its analogue (by replacing the amino acid at position 1 with a tyrosine) were docked respectively with MHC class Ⅰ molecule, followed by 600 ps molecular dynamics simulations. Results More powerful H-bonding interaction and hydrophobic interaction were found between the analogue and the MHC class Ⅰ molecule. Tyr7, Tyr171, and Tyr159 of pocket A within the binding cleft could form a network of hydrogen bonds that directly interacted with the peptide N-terminus. Moreover, there was a π-π stacking interaction between Trp167 and the aromatic P1 residues. Conclusion All these results strongly suggest that the analogue has higher affinity to MHC molecule, which is in good agreement with the experimental data.
出处 《免疫学杂志》 CAS CSCD 北大核心 2005年第6期514-517,共4页 Immunological Journal
基金 国家重大基础研究计划(2001CB510001) 国家自然科学基金(90208028 30490240)资助项目
关键词 MHCⅠ类分子 CTL 表位 分子对接 分子动力学 MHC class Ⅰ molecule CTL Epitope Molecular docking Molecular dynamics
  • 相关文献

参考文献9

  • 1Nikolich Zugich J,Slifka MK,Messaoudi I.The many important facets of T-cell repertoire diversity [J].Nat Rev Immunol,2004,4 (2):123-132.
  • 2Scardino A,GrossDA,AlvesP,etal.HER-2/neuand hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy [J].J Immunol,2002,168 (11):5900-5906.
  • 3Tangri S,Ishioka GY,Huang X,et al.Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wildtype peptide [J].J Exp Med,2001,194 (6):833-846.
  • 4Huarte E,Sarobe P,Lu J,et al.Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements [J].Clin Cancer Res,2002,8 (7):2336-2344.
  • 5Luty BA,Wasserman ZR,Stouten PFW,et al.A molecular mechanics/grid method for evaluation of ligand-receptor interactions [J].J Comp Chem,1995,16 (4):454-464.
  • 6Tao P ,Lai L .Protein ligand docking based on empirical method for binding affinity estimation [J].J Comput Aided Mol Des,2001,15 (5):429-446.
  • 7Wallace AC,Laskowski RA,Thornton JM.LIGPLOT:a program to generate schematic diagrams of protein-ligand interactions [J].Protein Eng,1995,8 (2):127-134.
  • 8Kitchen DB ,Decornez H ,Furr JR ,et al .Docking and scoring in virtual screening for drug discovery:methods and applications [J].Nat Rev Drug Discov,2004,3 (11):935-949.
  • 9Kirksey TJ,Pogue Caley RR,Frelinger JA,et al.The structural basis for the increased immunogenicity of two HIVreverse transcriptase peptide variant/class I major histocompatibility complexes [J].J Biol Chem,1999,274 (52):37259-37264.

同被引文献36

  • 1赵文娜,邹建卫,蒋勇军,马国正,俞庆森.基于HPPK靶标酶的分子对接研究——金属离子Mg^(2+)的影响[J].化学学报,2005,63(5):434-438. 被引量:5
  • 2Schmitz J, Reali E, Hodge W, et al. Identification of an interferon-inducible carcino embryonic antigen (CEA) CD8R T-cell epitope, which mediates tumor killing in CEA transgenicmice[J]. Cancer Res, 2002, 62 (17): 5058 - 5064.
  • 3Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Fh3 Ligand expanded dendritic ceils for tumor immunotherapy [J]. Proc Natl Acad Sci USA, 2001, 98 (15): 8809 - 8814.
  • 4Ayyoub MH, Mazarguil B, Monsarrat B, et al. A structure-based approach to designing non-natural peptides that can activate anti-melanoma cytotoxic T cells[J]. J Biol Chem, 1999, 274 (15): 10227 - 10234.
  • 5Stemmer C, Quesnel A, Prevost Blondel A, et al. Protection against lymphocytic choriomen in Girls virus infection induced by a reduced peptide bond analogue of the H-2K^D-restricted CD8 T cell epitope GP35[J]. J Biol Chem, 1999, 274 (9): 5550 - 5556.
  • 6Douat Casassus C, Marchand Geneste N, Diez E, et al. Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells [J]. J Med Chem, 2007, 50(7): 1598 - 1609.
  • 7Chen Y, Sidney J, Southwood S, et al. Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations[J]. J lmmunol, 1994,152 (6): 2874 - 2881.
  • 8Peace DJ, Smith JW, Oaen W, et al. Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras paptide[J]. J Exp Med, 1994, 179 (2): 473 - 479.
  • 9Borbulevych OY, Baxter TK, Yu Z, et al. Increased immuno- genicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design[J]. J Immunol, 2005,174 (8): 4812 - 4820.
  • 10Tang Y, Lin Z, Ni B, et al. An altered peptide ligand for naive cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity[J]. Cancer Immunol Immunother, 2007, 56 (3): 319 - 329.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部